Board of directors

Roger M Nitsch serves as CEO & President of Neurimmune, which he founded in 2006 together with Jan Grimm and Christoph Hock. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research, and as a pioneer in the development of therapeutic approaches for neurodegenerative diseases. A Potamkin Prize winner, Member of the German Academy of Sciences and Professor emeritus at the University of Zurich, Roger served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich.

Christoph Hock is a board-certified psychiatrist and an internationally recognized expert on Alzheimer's disease and related disorders. He co-founded Neurimmune in 2006 and acts as Chief Medical Officer (CMO). Previously, Christoph served as Vice-President Medicine and Science on the executive board of the University of Zurich, and as member of the Swiss National Science Foundation's Research Council. He currently holds a part-time professorship on Biological Psychiatry at the Institute for Regenerative Medicine (IREM), University of Zurich.

Jan Grimm is a neuroscientist with 20 years of experience in drug discovery and development in US and European biotech. Jan co-founded Neurimmune in 2006, and served as the company's founding CEO. Before joining Neurimmune he led the Alzheimer’s disease research efforts at Rinat Neuroscience Corp. in San Francisco that was acquired by Pfizer in 2006. He received a PhD degree from Max Delbrück Center for Molecular Medicine and Humboldt University Berlin.

Alfred W Sandrock joined the Neurimmune Board of Directors in 2022. Al is recognized as an outstanding industry leader who brought numerous transformational therapies for the treatment of neurological diseases to patients. He spearheaded the development of Tysabri®, Tecfidera®, Spinraza®, Plegridy®, and most recently Aduhelm^TM. In his 23-year career at Biogen, Al served in various functions including as an Executive Committee Member, Head of Research & Development and Chief Medical Officer. He holds an MD degree from Harvard Medical School and a PhD degree from Harvard University.